雅普1
肺癌
人口
医学
肿瘤科
环境卫生
生物
转录因子
基因
生物化学
作者
Catherine Allison Stewart,Kavya Ramkumar,Runsheng Wang,Yuanxin Xi,Alexa Halliday,Lixia Diao,Qi Wang,Alejandra G. Serrano,Sarah Groves,Simon Heeke,Azusa Tanimoto,Laura Kaiser,Yan Yang,Whitney E. Lewis,Jody V. Vykoukal,Mukulika Bose,Pedro Rocha,Loukia Georgiou Karacosta,Samir Hanash,Vito Quaranta
标识
DOI:10.1016/j.jtho.2026.103730
摘要
INTRODUCTION: SCLC is an aggressive neuroendocrine malignancy characterized by rapid onset of chemoresistance and poor clinical outcomes. Transcriptional heterogeneity among treatment-naive SCLC tumors underlies four transcriptional subtypes, each with distinct clinical vulnerabilities. Though previously hypothesized to delineate a distinct subtype, expression of YAP1 is largely absent from treatment-naive, pure SCLC. METHODS: Methods: To characterize relapsed SCLC, circulating tumor DNA, circulating tumor cells, and core needle biopsies from patients with SCLC and preclinical models following resistance to standard-of-care therapies were analyzed. RESULTS: In contrast to treatment-naive SCLC, these analyses reveal an emergent YAP1-positive cell population that coincides with treatment resistance. These YAP1-positive cells exhibit characteristics of drug-tolerant persister cells, including senescence, stemness, and plasticity, as YAP1-positive cells largely abandon features characteristic of SCLC to adopt those of large cell neuroendocrine carcinoma. As a result of this SCLC-like to large cell neuroendocrine carcinoma-like evolution, YAP1-positive cells lack several clinically relevant SCLC surface targets (i.e., DLL3, SEZ6) but are enriched for others (i.e., B7-H3, TROP2) CONCLUSIONS: We propose a model where YAP1-expressing cells emerge with SCLC treatment resistance and characterize a tenacious subpopulation capable of diverging from the treatment-naive lineage and adopting features to evade therapeutic response.
科研通智能强力驱动
Strongly Powered by AbleSci AI